CKD-712 is an orally active multi-target tetrahydroisoquinoline derivatived and a potent inhibitor of the NF-kappaB pathway[2]. CKD-712 selectively inhibits MMP-9 with no effect on MMP-2, downregulates the expression of TNF-alpha, IL-6, cyclin A, cyclin B, CDK-1 and other proteins, and activates the PI3K/Akt signaling pathway[1][2]. CKD-712 blocks the activation and nuclear translocation of NF-kappaB, downregulates inflammatory factors and pro-tumor metastatic proteins, and induces G2/M phase arrest in tumor cells and thereby inhibits the invasion of cancer cells[1][2]. CKD-712 can be used for the research of sepsis, myocardial ischemia-reperfusion injury and non-small cell lung cancer[1][2][3].
